title: Clinical grade of generation of dendritic cells for immunotherapy.
abstract: In order to develop a protocol for clinical grade generation of dendritic cells (DCs) for cancer immunotherapy, aphereses were performed with the continuous flow cell separator and materials were derived from 10 leukemia patients that had achieved complete remission. Peripheral blood monocytes were cultured in vitro with GM-CSF, IL-4 for 6 days, then TNF-(the TNF-group) or TNF-, IL-1, IL-6, PGE2 (the cytokine mixture group) were added to promote maturation. Cell number was counted by hematology analyzer, and phenotype study (CD1a, CD14, CD83) was carried out by flow cytometry, and the function of DCs was examined by mixed lymphocyte reaction. The results showed that (0.70+/-0.13)x10(7)/mL (the TNF-alpha group) and (0.79+/-0.04)x10(7)/mL (the cytokine mixture group) DCs were generated respectively in peripheral blood obtained by leucapheresis. The phenotypes were as follows: CD1a+ (74.65+/-4.45)%, CD83+ (39.50+/-4.16)%, CD14+ (2.90+/-1.76)% in TNF-alpha group, and CD1a+ (81.86+/-5.87)%, CD83+ (81.65+/-6.36)%, CD14+ (2.46+/-1.68)% in the cytokine mixture group. It was concluded that leucapheresis may be a feasible way to provide large number of peripheral blood monocytes for DC generation, and combined administration of TNF-, IL-1, IL-6, and PGE2 may greatly promote maturity.
authors.affiliation: Molecular Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Sicence and Technology, Wuhan 430030, China. tangduozhuang@tom.com
authors.forename: Duozhuang
authors.initials: D
authors.lastname: Tang
authors.forename: Si
authors.initials: S
authors.lastname: Tao
authors.forename: Yang
authors.initials: Y
authors.lastname: Cao
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Zhou
authors.forename: Ding
authors.initials: D
authors.lastname: Ma
authors.forename: Wei
authors.initials: W
authors.lastname: Huang
mesh_terms: D019496:Cancer Vaccines / Q000276:immunology; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000166:cytology* / Q000276:immunology / Q000637:transplantation; D005434:Flow Cytometry; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D015847:Interleukin-4 / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology; D007937:Leukapheresis / Q000379:methods*; D007938:Leukemia / Q000097:blood / Q000473:pathology; D007959:Lymphocyte Culture Test, Mixed; D009000:Monocytes / Q000166:cytology*
chemical_list: D019496:Cancer Vaccines; D015850:Interleukin-6; D015847:Interleukin-4; D016178:Granulocyte-Macrophage Colony-Stimulating Factor